Page 1

Global Biosimilar Monoclonal Antibodies Market: Trends and Forecasts up to 2023

INFINIUM GLOBAL RESEARCH


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

INTRODUCTION REPORT DESCRIPTION

A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancer. The Global Biosimilar Monoclonal Antibodies Market has experienced significant growth over the past few years, primarily due to patent expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure in emerging markets. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective treatment, collaboration with the local players and high profitability in the market are the key opportunities for the companies to invest in the biosimilar monoclonal antibodies market. As per the report the global biosimilar monoclonal Antibodies market was worth USD 496.3million in 2015 and it is projected to reach USD xxxx.x million, expanding at a CAGR of 42.8% between 2017 and 2023. This report estimates the market size of biosimilar monoclonal antibodies in terms of value (USD million) over the period of 2015 to 2023. The year 2015 are considered to be base years, and 2017 to 2023 is considered to be a forecast period. The market sizes for biosimilar monoclonal antibodiesby drug class, by application and by region are estimated in terms of value. This market research study provides detailed qualitative and quantitative analyses of the global biosimilar monoclonal antibodiesmarket. Additionally, the report provides a 2

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

comprehensive review of the major market drivers, restraints, opportunities in the global as well as regional markets of biosimilar monoclonal antibodies. The market analysis covers major geographic regions, such as North America, Europe, AsiaPacific, Latin America, and Rest of the World (RoW). The market size and forecasts are also given for these regions. This report provides insights into the market using analytical tools such as Porter’s five forces analysis and DRO analysis of biosimilar monoclonal antibodies market. Moreover, the study highlights current market trends and provides forecast from 2017 to 2023. We also have highlighted future trends in the global biosimilar monoclonal antibodies market that will impact the demand during the forecast period. The IGR- Growth Matrix analysis provided in this report highlights key investing markets in the world. This report will help manufacturers, suppliers and distributors to understand the present and future trends in this market and formulate their strategies accordingly. SEGMENTATION AND RESEARCH SCOPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION

Drug Class

Applications

Region

 Oncology  Rituximab  Infliximab  Abciximab  Trastuzumab

 Chronic and Autoimmune Diseases

 Adalimumab

 Growth Hormone Deficiency

 Bevacizumab

 Infectious Diseases

 North America  Europe  Asia-Pacific  Latin America  RoW

 Others

The report segments the global Biosimilar Monoclonal Antibodies market by drug class, applications, and region. On the basis of drug class the Biosimilar Monoclonal 3

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

Antibodies market is segmented as rituximab, Infliximab, Abciximab, Trastuzumab, Adalimumab and Bevacizumab. Based on application, the market has been segmented into Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases and others. The global biosimilar monoclonal antibodies market is analyzed covering the regions such as North America, South America, Europe, Asia- Pacific, Latin America and Rest of the World. RESEARCH METHODOLOGY

Infinium Global Research published reports are based on extensive primary and secondary research methods. The research begins with extensive exploration through secondary sources followed by primary research. With these research methods we were able to estimate the market size of the biosimilar monoclonal antibodies market, to identify the factors that promote the growth in this market as well as the factors that hamper the growth in the market. Comprehensive primary and secondary methods helped us to identify the trends in the market and to project the opportunities that the key players may get in the coming days.

RESEARCH METHODOLOGY: AN OUTLINE

Primary Research

Secondary research

4

• Primary sources of the information and data include • Industry Experts/ consultants • Top level executives in the key market players • Subject matter experts • Academicians and research scholars

• Secondary sources of the information and data include • Company annual reports • Government/institutional publications • Trade and associations’ journals • Databases • Websites and publications by research agencies • Others

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid data sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include • Company annual reports • Government/institutional publications • Trade and associations’ journals • Databases such as WTO, OECD, Hoovers, Factiva, and World bank, among others. • Websites and publications by research agencies • The World Health Organization • The U.S. FDA • Public Health England • American Society of Clinical Oncology • Government of Canada Publications, • The U.S. National Library of Medicine, National Institutes of Health • The Organisation for Professionals in Regulatory Affairs Ltd 5

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

DATA COLLECTION MATR IX: RESEARCH METHODOLOGY: DATA COLLECTION MATRIX

Demand Side analysis

Global market size (Consumption)

Supply Side Analysis

Production +Import -Export

Data collection matrix explains the triangulation of the data collected to arrive at the market size of the global biosimilar monoclonal antibodies market. The supply side analysis considers the production of biosimilar monoclonal antibodies. The supply side analysis also takes into consideration the suppliers and other stakeholders involved into supply of the biosimilar monoclonal antibodies. The demand side analysis considers the application areas of the biosimilar monoclonal antibodies market. In this approach the various industry players are considered. The country-wise sales values provide the data of consumption of biosimilar monoclonal antibodies in the regional as well as global markets. Moreover, this approach helps analyze the future trends and the market size of the global as well as regional biosimilar monoclonal antibodies market. In order to arrive at the market size as well as to validate the data findings from supply and demand side analyses. The market size is arrived at with an assumption of production = consumption in application segments.

6

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

RESEARCH APPROACHES

The study on global biosimilar monoclonal antibodies market provides deep insights into the trends and opportunities in the market for the forecast period 2017 to 2023. Moreover, the market estimates are provided in terms of revenue in USD million. The research also covers the analysis of the various segments in the global biosimilar monoclonal antibodies market. The estimates in the global biosimilar monoclonal antibodies market are based on both bottom-up and topdown approaches. RESEARCH APPROACHES- BOTTOM UP • •

Accumulation of the country level market size (sales value and volume) Regional market size of biosimilar monoclonal antibodies and its applications

• •

Segment revenue of the key players Country level market size by drug class and applications

Identifying key players in the biosimilar monoclonal antibodies market

Accumulation of the regional/country market size (sales value and volume) Global market size of product drug class and applications

In the bottom-up approach the revenues of the key players are determined and added to arrive at country or regional markets size. The country market sizes added to arrive at the regional market size. Further, the market size of the regions is added to arrive at the global market size of Biosimilar Monoclonal Antibodies market.

7

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

IGR- RESEARCH METHOD AND DATA TRIANGULATION SECONDARY SOURCES.

PRIMARY SOURCES

• World Health Organization

•Executives working in Application areas of biosimilar monoclonal antibodies such as oncology, and others.

• Government Agencies’ Publications • Industry news ‘ • American Society of Clinical Oncology

Infinium’s Data bank/Know how

• Government of Canada Publications, • The U.S. National Library of Medicine, National Institutes of Health

•C-level executives in the leading manufacturing companies of biosimilar monoclonal antibodies •Industry consultants •Laboratories and testing centers

• Annual Reports • Presentations • Company Websites

• Press Releases • News Articles • Journals

Primary Research

Secondary Research

• Paid Databases

Company Publications .

SUPPLY SIDE

• The Organization for Professionals in Regulatory Affairs Ltd

General. Publications

DEMAND SIDE

• Industry Publications

Data Triangulation and Information Sources

The market size of biosimilar monoclonal antibodies is determined based on the top down approach. The market size is validated using primary interview with the participants working in some of the leading players in the biosimilar monoclonal antibodies market. The primary interview participants typically include managers and CXO level executives of the leading players in this market. The primary interviews not only help identify the market size of the biosimilar monoclonal antibodies market but also identify the factors that promote the growth in the market and the factors that restrain the growth in this market. The views of primary respondents were reconciled to provide qualitative analysis of the biosimilar monoclonal antibodies market. The primary respondents also help identifying top 5-10 players and their possible market share in the respective country markets and in world market. The bottom-up approach is used to validate the global market size of biosimilar monoclonal antibodies. With the help of primary interviews and secondary research the market size of biosimilar monoclonal antibodies is determined for each country studied, which then is added to arrive at regional market size and thereby obtaining global market size. This in turn helps us to validate the market size of biosimilar monoclonal antibodies in the world market.

8

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

EXECUTIVE SUMMARY GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET HIGHLIGHTS, (USD MILLION)

The global biosimilar monoclonal antibodies market was worth USD 496.3 million in 2015 and it is projected to reach USD6365.1million in 2022, expanding at a CAGR of 42.8% between 2017 and 2023. The global biosimilar monoclonal antibodies market is driven by the factors such as rising demand for biosimilar drugs owing to their cost effectiveness, patent expiration of biologics, and prevalence of chronic diseases among geriatric population. However, unfavorable government regulations in developed economies and high cost associated with manufacturing process are likely to act as a primary restraining factors affecting the global biosimilar monoclonal antibodies market over the forecast period. Moreover, emerging markets owing to relaxed regulations are expected to provide more opportunities for the manufacturers of biosimilar drugs. Asia - Pacific dominates the world biosimilar monoclonal antibodies market in terms of dollar share, while North America is anticipated to grow at the highest CAGR over the forecast period. Asia- Pacific accounted for the largest market share of Biosimilar Monoclonal Antibodies and it is mainly driven by ease of regulations in approval of Biosimilar Monoclonal Antibodies and increasing demand for cost effective medicines among the middle classes of India and China. Some of the key players in the global Biosimilar Monoclonal Antibodies market are PFIZER, INC., Novartis AG, Reliance Life Sciences, Allergan plc, CoherusBioSciences, Inc., Biocon, Dr. Reddy’s Laboratories Ltd, BoehringerIngelheim GmbH., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, BIOCAD, GenorBioPharma Co. Ltd., and Celltrion, Inc. For More Details Get Free Sample Pages of this Premium Report: https://www.infiniumglobalresearch.com/reports/sample-request/72

9

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

MARKET OVERVIEW AND COMPETITIVENESS INTRODUCTION

‘Monoclonal antibody’ is defined as an antibody developed by using single cell clone or line of cell, it contains identical antibody. According to the Cancer Institute the monoclonal antibody is a type of protein made in the laboratory to bind to the substances in the body. These antibodies can be used to carry drugs, toxins, and/or radioactive substances directly to cancer cells. The National Center for Biotechnology Information defines biosimilar monoclonal antibodies as highly complex molecules derived from living cells or organisms. The Biosimilar demonstrate the characteristics and are identical to original drugs. The methods of manufacturing and distinct complexities are the important differences between biosimilar and original drugs. It has been assumed that the patent expiry of leading biologics is expected to drive the biosimilar market, however, the patent expiry does not imply the original method of manufacturing process of the manufacturer is available to develop the Biosimilar. Therefore it is not 100% confirmed that biosimilar products are identical to the biologics on a molecular level. This difference plays an important role in getting the licenses for the Biosimilar and its regulations. Several companies operating in this industry have been spending extensively on the research and development of the Biosimilar. There are several products in pipeline and clinical trial phase. Which in turn is likely to act as driving factor to promote the growth in this market over the forecast period. DRO ANALYSIS

DRO stands for drivers, restraints and opportunities. The DRO analysis involves, identifying the factors that are likely to have impact on the global biosimilar monoclonal antibodies market. It covers analysis of short term and long term impact of drivers and restraints. Through this analysis both short term and long term opportunities are identified. These opportunities present the investment options and new markets for the market players in the biosimilar monoclonal antibodies market.

10

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

Drivers refer to the factors that are expected to drive or boost the market size or demand for biosimilar monoclonal antibodies. The analysis involves identification of both demand side and supply side factors that drive the demand as well as environmental factor that favor the market conditions for growth of biosimilar monoclonal antibodies market both in short run and long run. DRIVERS, RESTRAINTS AND OPPORTUNITIES IN GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET •

Rising demand for biosimialr drugs owing to their cost effectiveness

Patent expiration of biologics

Prevalence of Chronic diseases among geriatric population

R

• •

Unfavorable government regulations in developed economies High cost associated with manufacturing process

O

• Growing demand for biosimilar monoclonal antibodies from emerging markets

D

Drivers

Restraints

Opportunities

DRIVERS Rising demand for biosimilar drugs owing to their cost effectiveness The conventional expenditure on the health issues such as cancer and arthritis is very huge and theirs is significant burden of healthcare expenditure on middle income group patients. Biosimilar are low cost alternatives that help patients reduce the cost burden as these are less costly than the conventional patented drugs. Moreover, the rise in healthcare services has helped the governments to 11

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

regulate the prices of the drugs that can only be possible from Biosimilar. Although, the customers from developed countries have preferences for generic biologics that have established brand name, the government authorities are now pressurizing the healthcare services to reduce the healthcare expenditure and recommend Biosimilar. As a result the authorization and approvals of Biosimilar is at higher rate nowadays to reduce the medical expenses of the governments as well as the patients. The European Commission and the U.S. FDA have approved several Biosimilar for clinical trials in 2014 and 2015. Thus, the cost effectiveness of biosimilar drugs is expected to drive the Biosimilar Monoclonal Antibodies market over the forecast period at a significant rate. P a t e n t e x p i r a t i o n o f b i o l o gi c s Several generic biologics/monopoly drugs are reaching to the expiry dates of the patents and the patents of the several drugs have expired since 2013 to 2016. The expiry of several monopoly drugs has provided opportunities for the biosimilar drugs industry over this period. Several companies both mid -sized and large -sized have already begun research on the popular monopoly drugs that are due to expire by 2020. The biosimilar market has direct relation with the expiration of patents due to fast growth in the pharmaceuticals industry. Moreover, rising demand from the emerging markets for low cost medicines have paved avenues for the biosimilar drugs as a result it is expected to boost the global biosimilar monoclonal antibodies market over the period of 2016 to 2022. RESTRAINTS U n f a vo r a b l e r e gu l a t i o n s i n D e ve l o p e d E c o n o m i e s In developed economies such as North America and Europe have more stringent regulations than developing economies in Latin America and Asia. This is primarily due to predominance of the high brand value/ monopoly drugs in the developed regions. Emerging countries such as China, India and Brazil have favorable regulations for the approval of Biosimilar due to cost effectiveness of these drugs. Biosimilar market in the U.S. European Union is intensely regulated by regulatory authorities, also manufacturers of biosimilar drugs are under intense pressure due to oligopoly of the generic drugs manufacturers. The leading companies also enjoy the patent protection in developed markets. Moreover, the reimbursement policies, adoption and promotion activities by third parties such as distributor, 12

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

retailer and emerging norms for the safety and quality of healthcare products are majorly influencing the Biosimilar market in developed economies. Moreover, the consumers in the developed regions have preference for the branded drugs for oncology and other chronic diseases, due to which the govt. authorities have less pressure of modification of regulations and this is in turn is expected to affect the growth of biosimilar market over the forecast period. H i gh c o s t a s s o c i a t e d wi t h m a n u f a c t u r i n g p r o c e s s Although, biosimilar are gaining popularity due to their cost effectiveness, there is huge prerequisite of capital and time for the development of these drugs. Moreover, developed economies have stringent regulations pertaining to the adoption of biosimilar. In order to launch the biosimilar drugs, the manufacturer is required to spend extensively on the research and development activities, moreover the cost of infrastructure and plants for the manufacturing of these biosimilar is likely to be very high. Furthermore, several companies with their biosimilar are yet to achieve significant revenue. Lesser adoption of biosimilar in the developed markets, which are high contributor to healthcare sector’s growth, is expected to have adverse effect over the forecast period. Although, the emerging markets present favorable conditions for the business of biosimilar, the level of production required to meet the demand is very high. To meet such a high level of demand the companies are required to produce biosimilar in bulk, for which the cost required is very high. Moreover, the cost associated with approvals and validation of these biosimilar is very high. Furthermore, the domestic players in the emerging markets pose serious threat to the international brands in terms of local reach and popularity. However, mergers and collaborations with local players is likely to pay avenues to the international players over the forecast period. Thus, high initial cost of manufacture and research and development is likely to be a significant restraining factor and is likely to have high impact over the forecast period. OPPORTUNITIES E m e r gi n g m a r ke t s p r e s e n t s i g n i f i c a n t o p p o r t u n i t i e s . Emerging economies present significant opportunities for the biosimilar medicines due to lack of regulations, and growing middle class. Emerging markets such as 13

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

China, India, Brazil and Russia also present large consumer pool. Moreover, underdeveloped markets of Africa and Asia also present significant opportunities biosimilar as they are low cost and effective. The governments in such countries focus on biosimilar as they help reduce their healthcare expenses and ease budgetary pressures. Latin America has diversified opportunities in biosimilar drugs market, which enables the local manufactures and foreign pharmaceutical companies to invest heavily. Local players are penetrating the market to produce and commercialize the biosimilar drugs of international quality. The biosimilar market in Latin America is foreseen to have tremendous growth due the introduction of novel biologics molecules. Some of the biosimilar in Latin America that are in development stage are given in the below table. IGR- GROWTH MATRIX ANALYSIS

Growth matrix developed by Infinium Global Research, also known as IGR-Growth Matrix helps understand the market situation of the business segments. It helps identify the most attractive segment for the investment purpose and helps the companies to make better decisions in strategy making. The IGR- Growth Matrix presents the zones that define the position of the drug class segment and application segment based on the market size, growth anticipated and the growth factors & historic growth. Following are the zones that IGR- Growth Matrix considers  Risky Zone: Low market size and low growth rate. Investment in this segment is risky  Retention Zone: High market size and low growth rate, the companies operating in this segment should retain their investments in this segment. Companies may focus on extensive marketing and advertisements  Consolidation zone: High growth rate and high market size, the companies operating in the segments that have high market size and high growth should focus on consolidating their market position in these segment. Mergers and acquisitions, extensive marketing programs, and new product developments can be used as marketing strategies to consolidate the market in these segments. 14

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

 Opportunity Zone: High growth low market size  Safe Zone: Moderate growth and moderate market size.

IGR- GROWTH MATRIX ANALYSIS BY REGION Growth Rate

Consolidation zone

Opportunity zone High

Low Risky zone

Retention zone Market Size High

Low Asia Pacific

Europe

NA

LATAM

RoW

According to IGR-Growth Matrix, Asia-Pacific and Europe regions fall in the consolidation zone. These two markets accounted for the largest and second largest market shares in 2014 and 2015, and are expected to grow at significant rates over the forecast period. Several drugs in pipeline in Latin American region and expiry of patents of several branded drugs in North America place these regions in Americas into opportunity zone. The manufacturers of biosimilar in these regions can focus more new product launches and introduction of new biosimilar drugs in these regions. Asia Pacific and Europe regions present significant potential to consolidate their market positions by undertaking awareness programs such as advertisements and promotions.

IGR- GROWTH MATRIX ANALYSIS BY DRUG CLASS 15

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

Growth Rate

Consolidation zone

Opportunity zone High

Low Risky zone

Retention zone Market Size High

Low

Rituximab

Infliximab

Abciximab

Trastuzumab

Adalimumab

Bevacizumab

The IGR matrix for drug class suggests that the rituximab and infliximab fall in the consolidation and retention zones. Which in turn suggests that the manufacturers of Biosimilar in this drug class should focus more on creating awareness about these drugs, they can undertake extensive promotional activities and marketing campaigns in the years to come. Other drugs classes fall under opportunity zone as there are several Biosimilar in these drug classes are under pipeline. The companies that have pipelines in these drug classes should focus more on new product developments and can undertake innovative marketing programs.

Get 15% Discount on this Premium Report: https://www.infiniumglobalresearch.com/reports/request-discount/72

16

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

IGR- GROWTH MATRIX ANALYSIS BYAPPLICATIONS Growth Rate

Consolidation zone

Opportunity zone High

Low Risky zone

Retention zone Market Size High

Low Oncology

Chronic and Autoimmune Diseases

Growth Hormone Deficiency

Infectious Disease

Others

Among the application segments the oncology segment falls into retention zone due to higher market size, other application areas fall under opportunity zone. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKETBY DRUG CLASS

INTRODUCTION

Biological drugs are derived from the living cells through biological processes and simulate the biological substances, for instance, hormones. The biosimilar drugs are similar to biological drugs in terms of characteristics such as safety, efficacy and quality. There have been several biosimilar drugs approved by the governments across the world, especially from, India and China. Biosimilar drugs are produced under standard manufacturing process and are regulated by the regulatory authorities and are tested before being prescribed. Monoclonal antibodies have become important in the treatments of several chronic diseases. The monoclonal antibodies have been significantly used as powerful human therapeutic agents. Globally, the demand for monoclonal antibodies has grown over USD 65 billion by 2015. There has been significant 17

ŠInfinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

growth in demand for biosimilar monoclonal antibodies over the past few years and there are several biosimilar monoclonal antibodies in pipeline by 2015-16. The report studies the biosimilar monoclonal antibodies by drug class such as rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. COMPANY PROFILES

OVERVIEW

The company profile chapter presents study of the key players in the world Biosimilar Monoclonal Antibodies market. The companies covered in this report include,PFIZER, INC., Novartis AG, Reliance Life Sciences, Allergan plc, CoherusBioSciences, Inc., Biocon, Dr. Reddy’s Laboratories Ltd, BoehringerIngelheim GmbH., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited,GenorBiopharma Co. Ltd, Celltrion Inc., and BIOCAD. The recent developments presented in every company profile provides insights into new updates and developments in the Biosimilar Monoclonal Antibodies market. It is also referred to as the competitive landscape in the industry. PFIZER, INC.

PFIZER, INC. is one of the largest pharmaceuticals company, engaged in manufacture of vaccines and injectable biologic medicine. It was founded in 1984 and it is headquartered in New York, US. The company operates in business segments such as Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare, and Global Established Pharmaceutical. The Global Innovative Pharmaceutical segment focuses on developing, registering and commercializing novel, value creating medicines that significantly improve patient’s lives. The Global Vaccines, Oncology and Consumer Healthcare segment is engaged in the development and commercialization of vaccines and products for oncology and consumer healthcare.

18

©Infinium Global Research


Global Biosimilar Monoclonal Antibodies Market: Trends and Forecast -2023

PFIZER, INC.: CONTACT INFO PFIZER, INC. Contact details Address: 235 East 42nd Street New York, New York 10017-5755 United States Tele: +1 212 733 2323 Fax: +1 212 573 2273 Website: http://www.pfizer.com/

Key Features No. of Employees: 97,900 No. of countries of operation: NA No. of SBUs/Subsidiaries: 6 (Agouron Pharmaceuticals, G.D. Searle, Greenstone, Hospira, InnoPharma, Parke-Davis, Pfizer UK)

Browse Detailed Description, TOC and Key Players Mentioned in this Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/globalbiosimilar-monoclonal-antibodies-market

19

©Infinium Global Research

Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecast  

A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclo...

Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecast  

A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclo...

Advertisement